B

BioXcel Therapeutics
D

BTAI

1.37000
USD
0.02
(1.48%)
مغلق
حجم التداول
2,558
الربح لكل سهم
-10
العائد الربحي
-
P/E
-0
حجم السوق
8,296,783
أصول ذات صلة
A
ALLO
-0.05500
(-5.02%)
1.04000 USD
B
BLUE
0.00500
(0.10%)
4.99000 USD
C
CRSP
-0.760
(-2.02%)
36.850 USD
E
EDIT
-0.07000
(-4.32%)
1.55000 USD
GILD
GILD
0.670
(0.63%)
107.390 USD
N
NTLA
-0.30500
(-3.22%)
9.17000 USD
PFE
PFE
0.110
(0.47%)
23.330 USD
REGN
REGN
-8.04
(-1.35%)
588.61 USD
S
SGMO
-0.02030
(-4.11%)
0.47370 USD
VRTX
VRTX
1.79
(0.41%)
435.79 USD
المزيد
الأخبار المقالات

العنوان: BioXcel Therapeutics Inc

القطاع: Healthcare
الصناعة: Biotechnology
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology.The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.